ABC transporters, atherosclerosis and inflammation

Atherosclerosis

Volumn 211, Issue 2, 2010, Pages 361-370

  Fitzgerald, Michael L ^a   Mujawar, Zahedi ^a   Tamehiro, Norimasa ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ABCA1; ABCG1; ABCG5; ABCG8; Atherosclerosis; Inflammation; Sitosterolemia; Tangier disease

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CHOLESTEROL; HETERODIMER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPID;

ATHEROSCLEROSIS; BIOGENESIS; CELL SURFACE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; GENE MUTATION; GENETIC DISORDER; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTESTINE CELL; LIPID RAFT; LIPID TRANSPORT; LIVER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SITOSTEROLEMIA; TANGIER DISEASE;

ANIMALS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; CORONARY VESSELS; HEPATOCYTES; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTESTINAL DISEASES; LIPID METABOLISM, INBORN ERRORS; LIPOPROTEINS; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; PHENOTYPE; PHYTOSTEROLS; TANGIER DISEASE;

EID: 77955268633     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.011     Document Type: Review

References (168)

1. Fitzgerald M.L., Xavier R., Haley K.J., et al. ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. J Lipid Res 2007, 48(3):621-632.
2. van Meer G., Voelker D.R., Feigenson G.W. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol 2008, 9(2):112-124.
3. Wymann M.P., Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008, 9(2):162-176.
4. Zuo Y., Zhuang D.Z., Han R., et al. ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters. J Biol Chem 2008, 283(52):36624-36635.
5. Rader D.J., Cohen J., Hobbs H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003, 111(12):1795-1803.
6. Fredrickson D.S.A.P., Avioli L.V., Goodman D.W., Goodman H.C. Tangier disease. Ann Intern Med 1961, 55:1016-1031.
7. Fredrickson D.S. The inheritance of high density lipoprotein deficiency (Tangier disease). J Clin Invest 1964, 43:228-236.
8. Assmann G., Herbert P.N., Fredrickson D.S., Forte T. Isolation and characterization of an abnormal high density lipoprotein in Tangier Diesase. J Clin Invest 1977, 60(1):242-252.
9. Assmann G., Simantke O., Schaefer H.E., Smootz E. Characterization of high density lipoproteins in patients heterozygous for Tangier disease. J Clin Invest 1977, 60(5):1025-1035.
10. Assmann G., Smootz E., Adler K., Capurso A., Oette K. The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins. J Clin Invest 1977, 59(3):565-575.
11. Bojanovski D., Gregg R.E., Zech L.A., et al. In vivo metabolism of proapolipoprotein A-I in Tangier disease. J Clin Invest 1987, 80(6):1742-1747.
12. Schaefer E.J., Blum C.B., Levy R.I., et al. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N Engl J Med 1978, 299(17):905-910.
13. Schaefer E.J., Kay L.L., Zech L.A., Brewer H.B. Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier). J Clin Invest 1982, 70(5):934-945.
14. Zannis V.I., Lees A.M., Lees R.S., Breslow J.L. Abnormal apoprotein A-I isoprotein composition in patients with Tangier disease. J Biol Chem 1982, 257(9):4978-4986.
15. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest 1995, 96(1):78-87.
16. Remaley A.T., Schumacher U.K., Stonik J.A., et al. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Vasc Biol 1997, 17(9):1813-1821.
17. Rogler G., Trumbach B., Klima B., Lackner K.J., Schmitz G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol 1995, 15(5):683-690.
18. Rust S., Walter M., Funke H., et al. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet 1998, 20(1):96-98.
19. Bodzioch M., Orso E., Klucken J., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease [see comments]. Nat Genet 1999, 22(4):347-351.
20. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency [see comments]. Nat Genet 1999, 22(4):336-345.
21. Lawn R.M., Wade D.P., Garvin M.R., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway [see comments]. J Clin Invest 1999, 104(8):R25-31.
22. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 [see comments]. Nat Genet 1999, 22(4):352-355.
23. Chroni A., Liu T., Fitzgerald M.L., Freeman M.W., Zannis V.I. Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry 2004, 43(7):2126-2139.
24. Fitzgerald M.L., Morris A.L., Chroni A., et al. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J Lipid Res 2004, 45(2):287-294.
25. Fitzgerald M.L., Morris A.L., Rhee J.S., et al. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 2002, 277(36):33178-33187.
26. Oram J.F., Lawn R.M., Garvin M.R., Wade D.P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000, 275(44):34508-34511.
27. Wang N., Silver D.L., Costet P., Tall A.R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000, 275(42):33053-33058.
28. Denis M., Haidar B., Marcil M., et al. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem 2004, 279(9):7384-7394.
29. Rigot V., Hamon Y., Chambenoit O., et al. Distinct sites on ABCA1 control distinct steps required for cellular release of phospholipids. J Lipid Res 2002, 43(12):2077-2086.
30. Hassan H.H., Denis M., Lee D.Y., et al. Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J Lipid Res 2007, 48(11):2428-2442.
31. Landry Y.D., Denis M., Nandi S., et al. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006, 281(47):36091-36101.
32. Vaughan A.M., Oram J.F. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 2003, 44(7):1373-1380.
33. Vedhachalam C., Duong P.T., Nickel M., et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem 2007, 282(34):25123-25130.
34. Lin G., Oram J.F. Apolipoprotein binding to protruding membrane domains during removal of excess cellular cholesterol. Atherosclerosis 2000, 149(2):359-370.
35. Smith J.D., Waelde C., Horwitz A., Zheng P. Evaluation of the role of phosphatidylserine translocase activity in ABCA1-mediated lipid efflux. J Biol Chem 2002, 277(20):17797-17803.
36. Williamson P., Halleck M.S., Malowitz J., et al. Transbilayer phospholipid movements in ABCA1-deficient cells. PLoS One 2007, 2(1):e729.
37. Takahashi Y., Smith J.D. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci USA 1999, 96(20):11358-11363.
38. Neufeld E.B., Remaley A.T., Demosky S.J., et al. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 2001, 276(29):27584-27590.
39. Neufeld E.B., Stonik J.A., Demosky S.J., et al. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem 2004, 279(15):15571-15578.
40. Chen W., Wang N., Tall A.R. A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. J Biol Chem 2005, 280(32):29277-29281.
41. Hassan H.H., Bailey D., Lee D.Y., et al. Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. J Biol Chem 2008, 283(17):11164-11175.
42. Denis M., Landry Y.D., Zha X. ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. J Biol Chem 2008, 283(23):16178-16186.
43. Faulkner L.E., Panagotopulos S.E., Johnson J.D., et al. An analysis of the role of a retroendocytosis pathway in ATP-binding cassette transporter (ABCA1)-mediated cholesterol efflux from macrophages. J Lipid Res 2008, 49(6):1322-1332.
44. Bared S.M., Buechler C., Boettcher A., et al. Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells. Mol Biol Cell 2004, 15(12):5399-5407.
45. Bowden K., Ridgway N.D. OSBP negatively regulates ABCA1 protein stability. J Biol Chem 2008, 283(26):18210-18217.
46. Buechler C., Boettcher A., Bared S.M., Probst M.C., Schmitz G. The carboxyterminus of the ATP-binding cassette transporter A1 interacts with a beta2-syntrophin/utrophin complex. Biochem Biophys Res Commun 2002, 293(2):759-765.
47. Drobnik W., Borsukova H., Bottcher A., et al. Apo AI/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic 2002, 3(4):268-278.
48. Munehira Y., Ohnishi T., Kawamoto S., et al. Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem 2004, 279(15):15091-15095.
49. Nofer J.R., Feuerborn R., Levkau B., et al. Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J Biol Chem 2003, 278(52):53055-53062.
50. Nofer J.R., Remaley A.T., Feuerborn R., et al. Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res 2006, 47(4):794-803.
51. Okuhira K., Fitzgerald M.L., Sarracino D.A., et al. Purification of ATP-binding cassette transporter A1 and associated binding proteins reveals the importance of beta1-syntrophin in cholesterol efflux. J Biol Chem 2005, 280(47):39653-39664.
52. Tamehiro N., Zhou S., Okuhira K., et al. SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter. Biochemistry 2008, 47(23):6138-6147.
53. Tsukamoto K., Hirano K., Tsujii K., et al. ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem Biophys Res Commun 2001, 287(3):757-765.
54. Yan D., Lehto M., Rasilainen L., et al. Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. Arterioscler Thromb Vasc Biol 2007, 27(5):1108-1114.
55. Yan D., Mayranpaa M.I., Wong J., et al. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J Biol Chem 2008, 283(1):332-340.
56. Hoffman H.N., Fredrickson D.S. Tangier disease (familial high density lipoprotein deficiency). Clinical and genetic features in two adults. Am J Med 1965, 39(4):582-593.
57. Schaefer E.J., Zech L.A., Schwartz D.E., Brewer H.B. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980, 93(2):261-266.
58. Clee S.M., Kastelein J.J., van Dam M., et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000, 106(10):1263-1270.
59. Cohen J.C., Kiss R.S., Pertsemlidis A., et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305(5685):869-872.
60. Kathiresan S., Melander O., Guiducci C., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40(2):189-197.
61. Willer C.J., Sanna S., Jackson A.U., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40(2):161-169.
62. Benton J.L., Ding J., Tsai M.Y., et al. Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 193(2):352-360.
63. Clee S.M., Zwinderman A.H., Engert J.C., et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001, 103(9):1198-1205.
64. Jensen M.K., Pai J.K., Mukamal K.J., Overvad K., Rimm E.B. Common genetic variation in the ATP-binding cassette transporter A1, plasma lipids, and risk of coronary heart disease. Atherosclerosis 2007, 195(1):e172-e180.
65. Frikke-Schmidt R., Nordestgaard B.G., Jensen G.B., Steffensen R., Tybjaerg-Hansen A. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol 2008, 28(1):180-186.
66. Frikke-Schmidt R., Nordestgaard B.G., Schnohr P., Steffensen R., Tybjaerg-Hansen A. Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population. J Am Coll Cardiol 2005, 46(8):1516-1520.
67. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299(21):2524-2532.
68. Morgan T.M., Krumholz H.M., Lifton R.P., Spertus J.A. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007, 297(14):1551-1561.
69. Chung S., Gebre A.K., Seo J., Shelness G.S., Parks J.S. A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion. J Lipid Res 2009, 49(11):2390-2401.
70. Aiello R.J., Brees D., Bourassa P.A., et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002, 22(4):630-637.
71. Joyce C.W., Wagner E.M., Basso F., et al. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem 2006, 281(44):33053-33065.
72. Singaraja R.R., Fievet C., Castro G., et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002, 110(1):35-42.
73. van Eck M., Bos I.S., Kaminski W.E., et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA 2002, 99(9):6298-6303.
74. Brunham L.R., Singaraja R.R., Duong M., et al. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29(4):548-554.
75. Yvan-Charvet L., Ranalletta M., Wang N., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007, 117(12):3900-3908.
76. Bhattacharyya A.K., Connor W.E. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974, 53(4):1033-1043.
77. Katayama T., Satoh T., Yagi T., et al. A 19-year-old man with myocardial infarction and sitosterolemia. Intern Med 2003, 42(7):591-594.
78. Kolovou G., Voudris V., Drogari E., Palatianos G., Cokkinos D.V. Coronary bypass grafts in a young girl with sitosterolemia. Eur Heart J 1996, 17(6):965-966.
79. Miettinen T.A. Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur J Clin Invest 1980, 10(1):27-35.
80. Mymin D., Wang J., Frohlich J., Hegele R.A. Image in cardiovascular medicine. Aortic xanthomatosis with coronary ostial occlusion in a child homozygous for a nonsense mutation in ABCG8. Circulation 2003, 107(5):791.
81. Salen G., Horak I., Rothkopf M., et al. Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis. J Lipid Res 1985, 26(9):1126-1133.
82. Salen G., Shore V., Tint G.S., et al. Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis. J Lipid Res 1989, 30(9):1319-1330.
83. Salen G., Tint G.S., Shefer S., Shore V., Nguyen L. Increased sitosterol absorption is offset by rapid elimination to prevent accumulation in heterozygotes with sitosterolemia. Arterioscler Thromb 1992, 12(5):563-568.
84. Beaty T.H., Kwiterovich P.O., Khoury M.J., et al. Genetic analysis of plasma sitosterol, apoprotein B, and lipoproteins in a large Amish pedigree with sitosterolemia. Am J Hum Genet 1986, 38(4):492-504.
85. Gregg R.E., Connor W.E., Lin D.S., Brewer H.B. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest 1986, 77(6):1864-1872.
86. Morganroth J., Levy R.I., McMahon A.E., Gotto A.M. Pseudohomozygous type II hyperlipoproteinemia. J Pediatr 1974, 85(5):639-643.
87. Nguyen L.B., Shefer S., Salen G., et al. A molecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis. J Clin Invest 1990, 86(3):923-931.
88. Belamarich P.F., Deckelbaum R.J., Starc T.J., et al. Response to diet and cholestyramine in a patient with sitosterolemia. Pediatrics 1990, 86(6):977-981.
89. Salen G., Kwiterovich P.O., Shefer S., et al. Increased plasma cholestanol and 5 alpha-saturated plant sterol derivatives in subjects with sitosterolemia and xanthomatosis. J Lipid Res 1985, 26(2):203-209.
90. Patel S.B., Salen G., Hidaka H., et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest 1998, 102(5):1041-1044.
91. Berge K.E., Tian H., Graf G.A., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290(5497):1771-1775.
92. Lee M.H., Lu K., Hazard S., et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001, 27(1):79-83.
93. Lu K., Lee M.H., Hazard S., et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001, 69(2):278-290.
94. Repa J.J., Berge K.E., Pomajzl C., et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002, 277(21):18793-18800.
95. Mulligan J.D., Flowers M.T., Tebon A., et al. ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens. J Biol Chem 2003, 278(15):13356-13366.
96. Murthy S., Born E., Mathur S.N., Field F.J. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J Lipid Res 2002, 43(7):1054-1064.
97. Neufeld E.B., Demosky S.J., Stonik J.A., et al. The ABCA1 transporter functions on the basolateral surface of hepatocytes. Biochem Biophys Res Commun 2002, 297(4):974-979.
98. Ohama T., Hirano K., Zhang Z., et al. Dominant expression of ATP-binding cassette transporter-1 on basolateral surface of Caco-2 cells stimulated by LXR/RXR ligands. Biochem Biophys Res Commun 2002, 296(3):625-630.
99. Graf G.A., Li W.P., Gerard R.D., et al. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest 2002, 110(5):659-669.
100. Klett E.L., Lee M.H., Adams D.B., Chavin K.D., Patel S.B. Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine. BMC Gastroenterol 2004, 4:21.
101. Graf G.A., Yu L., Li W.P., et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 2003, 278(48):48275-48282.
102. Zhang D.W., Graf G.A., Gerard R.D., Cohen J.C., Hobbs H.H. Functional asymmetry of nucleotide-binding domains in ABCG5 and ABCG8. J Biol Chem 2006, 281(7):4507-4516.
103. Glueck C.J., Speirs J., Tracy T., et al. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism 1991, 40(8):842-848.
104. Sudhop T., Gottwald B.M., von Bergmann K. Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism 2002, 51(12):1519-1521.
105. Assmann G., Cullen P., Erbey J., et al. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis 2006, 16(1):13-21.
106. Basso F., Freeman L.A., Ko C., et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J Lipid Res 2007, 48(1):114-126.
107. -/- mice. J Lipid Res 2004, 45(8):1429-1436.
108. Wu J.E., Basso F., Shamburek R.D., et al. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J Biol Chem 2004, 279(22):22913-22925.
109. Wilund K.R., Yu L., Xu F., et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol 2004, 24(12):2326-2332.
110. Silbernagel G., Fauler G., Renner W., et al. The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J Lipid Res 2009, 50(2):334-341.
111. Buch S., Schafmayer C., Volzke H., et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007, 39(8):995-999.
112. Gylling H., Hallikainen M., Pihlajamaki J., et al. Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J Lipid Res 2004, 45(9):1660-1665.
113. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000, 275(36):28240-28245.
114. Venkateswaran A., Laffitte B.A., Joseph S.B., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000, 97(22):12097-12102.
115. Venkateswaran A., Repa J.J., Lobaccaro J.M., et al. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000, 275(19):14700-14707.
116. Klucken J., Buchler C., Orso E., et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 2000, 97(2):817-822.
117. Vaughan A.M., Oram J.F. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 2005, 280(34):30150-30157.
118. Wang N., Lan D., Chen W., Matsuura F., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004, 101(26):9774-9779.
119. Kennedy M.A., Barrera G.C., Nakamura K., et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005, 1(2):121-131.
120. -/- bone marrow. Arterioscler Thromb Vasc Biol 2006, 26(10):2301-2307.
121. Lammers B., Out R., Hildebrand R.B., et al. Independent protective roles for macrophage Abcg1 and Apoe in the atherosclerotic lesion development. Atherosclerosis 2009, 205(2):420-426.
122. Out R., Hoekstra M., Hildebrand R.B., et al. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2006, 26(10):2295-2300.
123. -/- bone marrow. Arterioscler Thromb Vasc Biol 2006, 26(10):2308-2315.
124. Out R., Hoekstra M., Habets K., et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008, 28(2):258-264.
125. Wang X., Collins H.L., Ranalletta M., et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007, 117(8):2216-2224.
126. Francone O.L., Royer L., Boucher G., et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler Thromb Vasc Biol 2005, 25(6):1198-1205.
127. Koseki M., Hirano K., Masuda D., et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J Lipid Res 2007, 48(2):299-306.
128. Zhu X., Lee J.Y., Timmins J.M., et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008, 283(34):22930-22941.
129. Tang C., Liu Y., Kessler P.S., Vaughan A.M., Oram J.F. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009, 284(47):32336-32343.
130. Jahangiri A., de Beer M.C., Noffsinger V., et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009, 29(2):261-267.
131. McGillicuddy F.C., de la Llera Moya M., Hinkle C.C., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119(8):1135-1145.
132. Bensinger S.J., Bradley M.N., Joseph S.B., et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134(1):97-111.
133. Gonzalez N.A., Bensinger S.J., Hong C., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31(2):245-258.
134. Kocher O., Krieger M. Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr Opin Lipidol 2009, 20(3):236-241.
135. Acton S., Rigotti A., Landschulz K.T., et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271(5248):518-520.
136. Trigatti B., Rayburn H., Vinals M., et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999, 96(16):9322-9327.
137. Zhang Y., Da Silva J.R., Reilly M., et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 2005, 115(10):2870-2874.
138. Guo L., Song Z., Li M., et al. Scavenger receptor BI protects against septic death through its role in modulating inflammatory response. J Biol Chem 2009, 284(30):19826-19834.
139. Cai L., Ji A., de Beer F.C., Tannock L.R., van der Westhuyzen D.R. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008, 118(1):364-375.
140. Guyton J.R. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007, 18(4):415-420.
141. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345(22):1583-1592.
142. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
143. Paolini J.F., Mitchel Y.B., Reyes R., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008, 101(5):625-630.
144. Maccubbin D., Koren M.J., Davidson M., et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009, 104(1):74-81.
145. Masson D., Jiang X.C., Lagrost L., Tall A.R. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 2009, 50(Suppl.):S201-S206.
146. Curb J.D., Abbott R.D., Rodriguez B.L., et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004, 45(5):948-953.
147. Thompson A., Di Angelantonio E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299(23):2777-2788.
148. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97(12):2917-2923.
149. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406(6792):203-207.
150. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21):2109-2122.
151. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356(16):1620-1630.
152. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356(13):1304-1316.
153. Bloomfield D., Carlson G.L., Sapre A., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157(2):352-360 e2.
154. Cannon C.P., Dansky H.M., Davidson M., et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 2009, 158(4). 513-519 e3.
155. Schwartz G.G., Olsson A.G., Ballantyne C.M., et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009, 158(6). 896-901 e3.
156. Stein E.A., Stroes E.S., Steiner G., et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009, 104(1):82-91.
157. Laffitte B.A., Repa J.J., Joseph S.B., et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001, 98(2):507-512.
158. Chisholm J.W., Hong J., Mills S.A., Lawn R.M. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 2003, 44(11):2039-2048.
159. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002, 99(11):7604-7609.
160. Repa J.J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000, 14(22):2819-2830.
161. Joseph S.B., Laffitte B.A., Patel P.H., et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002, 277(13):11019-11025.
162. Katz A., Udata C., Ott E., et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009, 49(6):643-649.
163. Peng D., Hiipakka R.A., Dai Q., et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 2008, 327(2):332-342.
164. Quinet E.M., Basso M.D., Halpern A.R., et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 2009, 50:2358-2370.
165. Bloedon L.T., Dunbar R., Duffy D., et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008, 49(6):1344-1352.
166. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290(17):2292-2300.
167. Sacks F.M., Rudel L.L., Conner A., et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 2009, 50(5):894-907.
168. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297(15):1675-1682.